Marksans Pharma Share Price

    NSE
    262.7
    +3.20 (1.15%)
    MARKSANS • 04 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    37.35%

    3Y Annualised Return

    73.37%

    5Y Annualised Return

    50.64%

    The current prices are delayed, login or Open Demat Account for live prices.

    Marksans Pharma Stock Performance

    1W Return4.16
    1Y Return58.43
    Today's Low256.5
    Prev. Close259.50
    Mkt Cap (Cr.)11,920.47
    1M Return2.43
    3Y Return507.51
    52-Week High358.7
    Open260.05
    PE Ratio63.37
    6M Return-11.70
    Today's High265
    52-Week Low164
    Face Value1

    Marksans Pharma Company background

    Founded in: 1992
    Managing director: Mark Saldanha

    Marksans Pharma Limited, a globally recognized pharmaceutical company, has established itself as a key player in the pharmaceutical industry with a strong focus on research, manufacturing, marketing, and sale of pharmaceutical formulations. Originally incorporated as Tasc Pharmaceuticals Limited in April 1982, the company underwent a significant transformation when it was renamed Marksans Pharma Limited following a Scheme of Amalgamation that took effect on October 10, 2005. This transition marked the beginning of Marksans Pharma's journey to becoming a trusted name in healthcare, with its innovative solutions and commitment to quality playing a central role in its growth.

    In 2005, Marksans Pharma underwent a pivotal change when it amalgamated with M/s Marksans Pharma Limited (formerly Glenmark Laboratories Limited). This merger, approved by a High Court order on August 19, 2005, allowed Marksans Pharma to consolidate its resources, expand its capabilities, and issue necessary shares to the shareholders of the amalgamating entity. This strategic move provided a robust platform for the company’s future endeavors, enabling it to diversify its product portfolio and strengthen its position in the pharmaceutical market.

    Marksans Pharma’s growth story is deeply intertwined with its strategic acquisitions that have helped it establish a strong international footprint. In 2005, the company acquired a majority stake in Nova Pharmaceuticals Australasia Private Limited, marking its entry into the Australian market. This acquisition enabled Marksans Pharma to tap into a new customer base and leverage Nova’s local expertise.

    Building on this momentum, Marksans Pharma expanded further into the European market in 2008 by acquiring two UK-based companies: Bell, Sons & Company (Druggists) Limited and Relonchem Limited. These acquisitions provided the company with access to established distribution networks in the UK and Europe, allowing it to deliver high-quality pharmaceutical products to a broader audience.

    Marksans Pharma’s global expansion continued with its entry into the US market, a significant milestone in its history. In 2011, the company achieved its first Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (USFDA), marking its readiness to compete in one of the most stringent and lucrative pharmaceutical markets globally.

    In 2015, Marksans Pharma further solidified its presence in the US by acquiring Time-Cap Laboratories Inc., a move that not only expanded its production capabilities but also enhanced its ability to meet the growing demand for generic pharmaceuticals in the region. This acquisition underscored the company’s strategic focus on gaining a foothold in key international markets.

    Marksans Pharma’s commitment to innovation is evident in its continuous investment in research and development (R&D). In the financial year 2017-18, the company launched its CNS-Cerebella division, which was dedicated to developing and marketing products targeting the central nervous system. This division underscored Marksans Pharma’s focus on addressing complex healthcare challenges and meeting the unmet needs of patients globally.

    The launch of soft gelatin capsules, a niche product category, further demonstrated the company’s ability to innovate and introduce unique formulations. During the same period, Marksans Pharma launched two new products and received a Complete Response Letter (CRL) for four ANDAs, bringing it closer to expanding its product range in the US market.

    To support its innovation-driven growth, Marksans Pharma commissioned a new R&D center in Navi Mumbai in 2019-20, complementing its existing facility in Verna, Goa. These state-of-the-art facilities have enabled the company to focus on developing complex generics and novel drug delivery systems, aligning with its vision of becoming a leader in the pharmaceutical industry.

    Marksans Pharma continues to build on its legacy of excellence and strategic growth. In April 2023, the company acquired the business of Tevapharm India Private Limited, a move that significantly enhanced its manufacturing capabilities. This acquisition involved taking over Tevapharm’s pharmaceutical formulations business in Verna, Goa, as a going concern on a slump sale basis. By integrating this facility into its operations, Marksans Pharma reinforced its position as a leading manufacturer of high-quality pharmaceutical products.

    The Marksans Pharma Share Price serves as a reliable indicator of the company’s robust financial performance and its consistent efforts to create value for stakeholders. Over the years, the share price has been influenced by the company’s strategic acquisitions, innovative product launches, and successful expansion into international markets. The company’s ability to adapt to changing market dynamics and its relentless focus on quality and compliance have bolstered investor confidence, making Marksans Pharma a compelling choice in the pharmaceutical sector.

    Marksans Pharma’s reputation for excellence is built on its unwavering commitment to quality and compliance. The company’s facilities in Goa and Navi Mumbai adhere to stringent regulatory standards, ensuring that its products meet the highest levels of safety and efficacy. Its R&D centers are equipped with advanced technologies and staffed by a team of skilled professionals dedicated to developing innovative solutions for diverse therapeutic areas.

    Looking ahead, Marksans Pharma is poised to continue its growth trajectory by leveraging its strong R&D capabilities, expanding its global footprint, and introducing innovative products. The company’s focus on complex generics, coupled with its strategic acquisitions, positions it to capture new opportunities in the pharmaceutical market.

    With a robust product pipeline, a growing international presence, and a steadfast commitment to quality, Marksans Pharma is well-equipped to address the evolving needs of patients and healthcare providers worldwide. As the company embarks on its next phase of growth, the Marksans Pharma Share Price is expected to reflect its ongoing success and its ability to deliver sustainable value to its stakeholders.

    Marksans Pharma Limited has come a long way since its inception as Tasc Pharmaceuticals Limited in 1982. Through strategic amalgamations, global acquisitions, innovative product launches, and a strong focus on R&D, the company has transformed into a global pharmaceutical powerhouse. Its relentless pursuit of excellence, combined with its ability to adapt to changing market dynamics, ensures its relevance in an increasingly competitive industry. As it continues to expand its global footprint and enhance its capabilities, Marksans Pharma remains committed to delivering high-quality pharmaceutical solutions that improve the lives of patients around the world.

    As of 04 Jul, 2025, Marksans Pharma share price is ₹263. The stock opened at ₹260 and had closed at ₹259.5 the previous day. During today’s trading session, Marksans Pharma share price moved between ₹256.50 and ₹265.00, with an average price for the day of ₹260.75. Over the last 52 weeks, the stock has recorded a low of ₹164.00 and a high of ₹358.70. In terms of performance, Marksans Pharma share price has declined by 11.7% over the past six months and has increased by 37.35% over the last year.

    Read More
    Marksans Pharma SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹78,84,772 (+21.30%)

    Daily SIP of 25,000 would have become 78,84,772 in 1 year with a gain of 13,84,772 (+21.30%)

    View details of Market Depth

    Marksans Pharma Fundamental

    Market Cap (in crs)

    11,920.47

    Face Value

    1

    Turnover (in lacs)

    2,842.93

    Key Metrics

    Qtr Change %
    26.67% Fall from 52W High
    27.3
    Dividend yield 1yr %
    Below industry Median
    0.2

    Marksans Pharma Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Marksans Pharma Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    708.46 Cr
    681.85 Cr
    641.92 Cr
    590.62 Cr
    560.01 Cr
    Marksans Pharma Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    2693.22 Cr
    2227.83 Cr
    1911.45 Cr
    1532.69 Cr
    1382.88 Cr
    1134.54 Cr
    Marksans Pharma Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    90.73 Cr
    105.07 Cr
    97.76 Cr
    89.07 Cr
    77.64 Cr
    Marksans Pharma Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    382.62 Cr
    314.9 Cr
    265.32 Cr
    186.81 Cr
    238.54 Cr
    120.75 Cr

    Marksans Pharma Result Highlights

    • Marksans Pharma Ltd reported a 18.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16.0%.

    • Its expenses for the quarter were down by 15.9% QoQ and up 21.2% YoY.

    • The net profit decreased 26.1% QoQ and decreased 6.1% YoY.

    • The earnings per share (EPS) of Marksans Pharma Ltd stood at 1.7 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Marksans Pharma

    Promoter
    43.9%
    Foreign Institutions
    22.2%
    Mutual Funds
    3.4%
    Domestic Institutions
    4.5%
    Public
    29.4%
    Promoter
    43.9%
    Foreign Institutions
    22%
    Mutual Funds
    3.2%
    Domestic Institutions
    4.2%
    Public
    29.9%
    Promoter
    43.9%
    Foreign Institutions
    21.3%
    Mutual Funds
    3%
    Domestic Institutions
    4.1%
    Public
    30.7%
    Promoter
    43.9%
    Foreign Institutions
    18.6%
    Mutual Funds
    2.8%
    Domestic Institutions
    3.7%
    Public
    33.8%
    Promoter
    43.8%
    Foreign Institutions
    15.6%
    Mutual Funds
    4.2%
    Domestic Institutions
    5.1%
    Public
    35.4%
    Promoter
    43.8%
    Foreign Institutions
    15.6%
    Mutual Funds
    3.8%
    Domestic Institutions
    4.7%
    Public
    35.8%

    Marksans Pharma Technical Analysis

    Moving Averages Analysis
    262.7
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    258.90
    10Day EMA
    255.90
    12Day EMA
    255.30
    20Day EMA
    253.40
    26Day EMA
    251.90
    50Day EMA
    246.50
    100Day EMA
    244.00
    200Day EMA
    239.60
    5Day SMA
    260.00
    10Day SMA
    253.00
    20Day SMA
    253.10
    30Day SMA
    254.00
    50Day SMA
    245.00
    100Day SMA
    232.40
    150Day SMA
    250.90
    200Day SMA
    261.90
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    446903 Rs
    1135791 Rs
    Week Rs
    386932 Rs
    978775 Rs
    Month Rs
    551135 Rs
    1277360 Rs
    261.52
    Pivot
    Resistance
    First Resistance
    266.53
    Second Resistance
    270.02
    Third Resistance
    275.03
    Support
    First Support
    258.03
    Second support
    253.02
    Third Support
    249.53
    Relative Strength Index
    61.38
    Money Flow Index
    51.47
    MACD
    3.38
    MACD Signal
    2.60
    Average True Range
    8.58
    Average Directional Index
    17.28
    Rate of Change (21)
    2.02
    Rate of Change (125)
    -11.85
    Name
    Holding Percent
    UTI-HEALTHCARE FUND
    1.41
    KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK SPECIAL OPPORTUNITIES FUND
    1.05
    MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    2.32
    ORBIMED ASIA IV MAURITIUS FVCI LIMITED
    10.88

    Marksans Pharma Latest News

    30 JUN 2025 | Monday

    Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    25 JUN 2025 | Wednesday

    Marksans Pharma Ltd - 524404 - Closure of Trading Window

    19 JUN 2025 | Thursday

    Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    View More

    Marksans Pharma Share Price FAQs

    Marksans Pharma share price is ₹262.7 in NSE and ₹263.15 in BSE as on 4/7/2025.

    Marksans Pharma share price in the past 1-year return was 58.42. The Marksans Pharma share hit a 1-year low of Rs. 164 and a 1-year high of Rs. 358.7.

    The market cap of Marksans Pharma is Rs. 11920.47 Cr. as of 4/7/2025.

    The PE ratios of Marksans Pharma is 63.37 as of 4/7/2025.

    The PB ratios of Marksans Pharma is 8.61 as of 4/7/2025

    The Mutual Fund Shareholding in Marksans Pharma was 3.37% at the end of 4/7/2025.

    You can easily buy Marksans Pharma shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Marksans Pharma share price is ₹358.7 and ₹164 as of 4/7/2025.

    Please be aware that Marksans Pharma stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.53
    +0.26 (+0.40%)
    139.24
    -0.46 (-0.33%)
    689.05
    -1.35 (-0.20%)
    2,599.10
    -12.10 (-0.46%)
    166.67
    -0.85 (-0.51%)
    391.40
    +0.75 (+0.19%)
    163.01
    -2.90 (-1.75%)
    261.40
    +0.55 (+0.21%)
    427.55
    +1.30 (+0.30%)
    401.00
    +1.10 (+0.28%)
    Top Gainers
    925.30
    +15.15 (+1.66%)
    1,640.70
    +22.00 (+1.36%)
    1,307.40
    +16.10 (+1.25%)
    1,442.80
    +16.90 (+1.19%)
    270.05
    +3.00 (+1.12%)
    Top Losers
    5,456.00
    -735.00 (-11.87%)
    163.01
    -2.90 (-1.75%)
    5,629.00
    -87.00 (-1.52%)
    1,655.20
    -16.70 (-1.00%)
    12,646.00
    -106.00 (-0.83%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -